Acorda Therapeutics (ACOR) Tops Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Acorda Reports Second Quarter 2020 Financial Results
August 4, 2020 4:00 PM EDTINBRIJA® (levodopa inhalation powder) 2Q 2020 net revenue of $4.7 million AMPYRA® (dalfampridine) 2Q 2020 net revenue of $26.1 million INBRIJA dispensed cartons increase 13% over 1Q 2020
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2020.
We were pleased with INBRIJAs... More
